CRI CEO and Director of Scientific Affairs Jill O’Donnell-Tormey, PhD, will co-moderate a panel discussion titled, \u00abNavigating Unique Challenges that Female Leaders Face in Immuno-Oncology\u00bb on February 8, 2023, along with co-moderator Katie McCarthy, Chief Innovation Officer, Halloran Consulting Group. Panelists include Lisa Butterfield, PhD, Adjunct Professor of Microbiology and Immunology at the University of California, San Francisco; Priti Hegde, PhD, CSO, Foundation Medicine; and Raluca Verona, PhD, Head, Heme Malignancies, Translational Research, Janssen R&D. The discussion will address unconscious bias and negotiation skills, followed by a Q&A.<\/p>\n\n\n\n
CRI Anna-Maria Kellen Clinical Accelerator and Venture Fund Research Analyst Ana Rosa S\u00e1ez Ib\u00e1\u00f1ez, PhD, will participate in a panel titled, \u00abDeveloping a Strategic Diversity and Inclusion Plan and Practical Execution in Clinical Trials\u00bb on February 8, 2023. Key topics include FDA guidance and requirement for diversity plans and how these requirements are translated into practice. Adrella Allen, PharmD, Director, Clinical Trial Patient Diversity, Global Clinical Trial Operations, Merck Research Labs, leads the panel.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"
CRI CEO and Director of Scientific Affairs Jill O’Donnell-Tormey, PhD, will co-moderate a panel discussion titled, \u00abNavigating Unique Challenges that Female Leaders Face in Immuno-Oncology\u00bb on February 8, 2023, along with co-moderator […]<\/p>\n","protected":false},"featured_media":27332,"template":"","events_categories":[203],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-27331","cri_events","type-cri_events","status-publish","has-post-thumbnail","hentry","events_categories-cri-speaks"],"acf":[],"yoast_head":"\n